Screener
Ligand Pharmaceuticals LGND Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,006,702 | $174,927 |
| Short-term investments | 351,056 | 558,594 |
| Accounts receivable, net | 67,011 | 59,601 |
| Inventory | 10,263 | 9,126 |
| Short-term portion of financial royalty assets, net | 12,982 | 22,792 |
| Income taxes receivable | 2,911 | 1,446 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's short-term investments?
- Ligand Pharmaceuticals (LGND) reported short-term investments of $351.06M in Q2 2026.
- How has Ligand Pharmaceuticals's short-term investments changed year-over-year?
- Ligand Pharmaceuticals's short-term investments increased by 97.9% year-over-year, from $177.35M to $351.06M.
- What is the long-term trend for Ligand Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's short-term investments has grown at a 9.0% compound annual growth rate (CAGR), from $363.57M to $558.59M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Ligand Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude